RPS6KA1 and cancer: The MAPK signaling pathway has been shown to be activated in many cancers that are resistant to drugs [27], and our study found that RPS6KA1, CACNA1B, and MAPK8IP3 were significantly enriched in the MAPK signaling pathway.